Apollo Hospitals Share News - Latest Updates, Live News & More

Latest news about Apollo Hospitals

Apollo Hospitals Subsidiary Completes Rs 1,650 Million Acquisition of Bangalore Hospital 5 hrs ago Today

Apollo Hospitals Enterprise Limited completed a Rs 1,650 million acquisition of Belenus Champion Hospitals Private Limited through its subsidiary Imperial Hospital and Research Centre Limited. The deal involves a 125-bed hospital in Bangalore that will be expanded to 175 beds by Q1 FY27, with total investment reaching Rs 3,000 million including upgrades and expansion costs.

Apollo Hospitals Reports Strong Q3FY26 Results with 17% Revenue Growth and Rs. 10 Interim Dividend 11 hrs ago Yesterday

Apollo Hospitals Enterprise Ltd. Records Rs. 55.83 Crore NSE Block Trade 4 days ago

Apollo Hospitals Enterprise Limited Schedules Q3 FY26 Earnings Conference Call for February 11, 2026 Jan 30, 2026

Apollo Hospitals Enterprise Gets CRISIL AA+ Rating Reaffirmation with Positive Outlook Revision Jan 27, 2026

More news about Apollo Hospitals

27Jan 26

Schroder Investment Management reduces stake in Apollo Hospitals Enterprise Ltd to 2.99%

Schroder Investment Management disclosed a reduction in its Apollo Hospitals Enterprise Ltd shareholding from 3.14% to 2.99% following the sale of 206,610 shares on 21 January 2026. The transaction was conducted through open market sales and represents a 0.14% decrease in the total share capital. The disclosure was filed under SEBI Regulation 29(2) with both NSE and BSE, with Schroder entities operating as discretionary fund managers and not belonging to the promoter group.

20Jan 26

Apollo Hospitals Enterprise Receives Approval to Acquire Additional 30.58% Stake in Apollo Health And Lifestyle

Apollo Hospitals Enterprise has secured regulatory permission to acquire an additional 30.58% stake in Apollo Health And Lifestyle, its wellness-focused subsidiary. This strategic acquisition will increase the healthcare major's ownership and control in the health and lifestyle segment, potentially creating synergies within its integrated healthcare ecosystem and strengthening its position in the wellness market.

16Jan 26

Apollo Hospitals Board Meeting Scheduled for February 10, 2026 to Consider Q3FY26 Financial Results

Apollo Hospitals Enterprise Limited has announced a board meeting on February 10, 2026 to approve Q3FY26 unaudited financial results for the three and nine months ended December 31, 2025. The meeting will cover both standalone and consolidated statements along with related matters. Trading window restrictions are in effect from January 1, 2026 until February 12, 2026 for promoters, directors, connected persons and designated employees in compliance with SEBI insider trading regulations.

16Jan 26

Apollo Hospitals Enterprise Schedules Q3 Results Consideration for February 10

Apollo Hospitals Enterprise has scheduled the consideration of its third quarter financial results for February 10. The company has formally communicated this date to stakeholders and market participants, providing advance notice for the upcoming financial disclosure. This announcement represents a key corporate milestone for the healthcare major and demonstrates the company's commitment to transparent financial reporting practices.

13Jan 26

Apollo Hospitals Enterprise Ltd. Records ₹16.65 Crore Block Trade on NSE

Apollo Hospitals Enterprise Ltd. completed a major block trade on NSE worth ₹16.65 crores, involving 22,947 shares at ₹7,257.00 per share. This institutional transaction highlights significant investor activity in the leading healthcare provider's stock.

13Jan 26

Apollo Hospitals Demerger Strategic Business Decision, Not Family Rift: Suneeta Reddy

Apollo Hospitals' restructuring to spin off pharmacy and digital health businesses is a strategic board decision for shareholder value creation, not family-driven, according to MD Suneeta Reddy. Apollo HealthCo targets FY27 listing with 20% growth projections versus 18% for hospitals business. The company focuses on preventive healthcare and selective expansion across metros and Tier-I cities.

10Jan 26

Apollo Hospitals' Lower Margins Explained: Diversified Business Model Impact on Profitability

Apollo Hospitals reports lower consolidated margins (15% EBITDA, 7.8% net) compared to peers due to diversified business model including low-margin pharmacy distribution (₹2,660 cr revenue, ₹73 cr profit) and loss-making diagnostics (₹474 cr revenue, ₹6 cr loss). Standalone hospital operations achieve competitive 25% EBITDA margin, indicating core business strength. Company is demerging pharmacy and digital health businesses to unlock value and improve margin clarity.

09Jan 26

Apollo Hospitals, Max Healthcare Face Further Earnings Downgrades Amid Sector Expansion Concerns

Macquarie reiterated 'Underperform' ratings on Apollo Hospitals and Max Healthcare, raising Apollo's price target to ₹6,230 while maintaining Max Healthcare at ₹825. Both stocks have underperformed Nifty 50 by 14% in 2025, with the brokerage expecting continued earnings downgrades. The firm cited aggressive sector expansion plans, with eight hospital chains adding 6,000+ beds by FY27, creating potential EBITDA drag not reflected in current estimates.

09Jan 26

Macquarie Maintains Underperform Rating on Apollo Hospitals, Raises Target Price to ₹6,230

Macquarie has maintained its Underperform rating on Apollo Hospitals while raising the target price to ₹6,230 from ₹5,700, marking a 9.3% upward revision. Despite the higher valuation, the brokerage continues its cautious stance, suggesting expectations of below-market returns while acknowledging some improvement in the company's fundamentals.

08Jan 26

Apollo Hospitals Enterprise Executes ₹236.09 Crore NSE Block Trade at ₹7,388.00 Per Share

Apollo Hospitals Enterprise Limited completed a substantial block trade on NSE worth ₹236.09 crores, involving approximately 319,564 shares at ₹7,388.00 per share. This large-volume institutional transaction highlights continued investor interest in the healthcare major and represents significant market activity in India's healthcare sector.

31Dec 25

Apollo Hospitals Enterprise Ltd. Records ₹17.65 Crore NSE Block Trade at ₹6,998 Per Share

Apollo Hospitals Enterprise Ltd. executed a significant NSE block trade worth ₹17.65 crores involving 25,217 shares at ₹6,998.00 per share. The transaction demonstrates substantial institutional investor activity and represents efficient execution of large-volume trading requirements in the leading healthcare services provider's stock.

31Dec 25

Apollo Hospitals Acquires 51% Stake in Healthcare Startup to Enhance Digital Services

Apollo Hospitals has acquired a 51% majority stake in a healthcare startup as part of its strategic initiative to enhance digital services and improve patient care delivery. This acquisition demonstrates the hospital chain's commitment to leveraging technology and innovation in healthcare, positioning the company to better compete in the evolving digital healthcare landscape while maintaining its market leadership position.

24Dec 25

Apollo Hospitals Receives NSE No-Objection for Composite Scheme Implementation

Apollo Hospitals Enterprise Limited has secured NSE approval for its composite scheme of arrangement involving demerger of business undertaking into Apollo Healthtech Limited and amalgamation of two transferor companies. The approval comes with comprehensive regulatory conditions including mandatory disclosures, NCLT filing authorization, and a six-month validity period for scheme implementation.

08Nov 25

Apollo Hospitals Secures Approval for Employee Stock Option Plan 2024

Apollo Hospitals Enterprise Limited (AHEL) has obtained in-principle approval from BSE and NSE for its Employee Stock Option Plan 2024. The plan allows for a maximum of 21,56,770 shares with a face value of Rs. 5 each. The approval, dated November 7, 2025, comes with conditions including regulatory compliance, adherence to listing agreements, and legal requirements. AHEL must notify exchanges after share allotment and pay prescribed fees. The exchanges reserve the right to withdraw approval if information is found to be incomplete or non-compliant.

07Nov 25

Apollo Hospitals Reports Strong Q2 Results, Plans 1,600 Bed Expansion

Apollo Hospitals Enterprise Ltd announced robust Q2 financial results with 13% YoY growth in consolidated revenue to Rs. 6,304.00 Crore, 15% increase in EBITDA to Rs. 941.00 Crore, and 26% rise in PAT to Rs. 477.00 Crore. The company plans to add 1,600 beds over the next 14 months, targeting 18% revenue growth in its hospital business over three years. Apollo also reported growth across its Healthcare Services, Apollo Health and Lifestyle Limited, and Apollo HealthCo divisions. The company continues to focus on clinical excellence and technological innovation, including AI-driven healthcare solutions.

06Nov 25

Apollo Hospitals Reports Strong Q2 FY26 Results with 13% Revenue Growth and 26% PAT Increase

Apollo Hospitals Enterprise Ltd announced robust Q2 FY26 financial results. Consolidated revenue grew 13% YoY to Rs. 6,304.00 crore, EBITDA increased 15% to Rs. 941.00 crore, and PAT surged 26% to Rs. 477.00 crore. Healthcare Services division saw 9% revenue growth, AHLL grew 17%, and Apollo HealthCo reported 17% growth. The company operated 8,050 beds with 69% occupancy and expanded its pharmacy network to 6,928 stores. Apollo 24/7 achieved a GMV of Rs. 723.00 crore, growing 16% YoY. The company continues to focus on technological innovation and clinical excellence.

06Nov 25

Apollo Hospitals Reports Strong Q2 FY26 Growth with 26% Jump in Net Profit

Apollo Hospitals Enterprise Ltd announced robust Q2 FY26 results, showing significant growth across all segments. Consolidated revenue increased by 13% to ₹6,304.00 crore, EBITDA grew by 15% to ₹941.00 crore, and PAT rose by 26% to ₹477.00 crore year-over-year. Healthcare Services revenue grew 9% to ₹3,169.00 crore, AHLL revenue increased 17% to ₹474.00 crore, and Apollo HealthCo revenue rose 17% to ₹2,661.00 crore. The company maintained 69% hospital occupancy, expanded its pharmacy network to 6,928 stores, and saw 16% growth in Apollo 24/7's GMV. Strategic developments included launching new healthcare facilities and receiving approval for a group restructuring plan.

14Oct 25

Apollo Hospitals to Hold Board Meeting for Q2 FY2026 Results on November 6, 2025

Apollo Hospitals Enterprise Ltd has announced a Board of Directors meeting on November 6, 2025, to review and approve unaudited financial results for Q2 FY2026, covering the three and six months ended September 30, 2025. The company has implemented a trading window closure from October 1, 2025, to November 8, 2025, for promoters, directors, connected persons, and designated employees in compliance with SEBI regulations.

24Sept 25

Apollo Hospitals Secures CCI Approval for Strategic Composite Scheme

Apollo Hospitals Enterprise Limited has obtained approval from the Competition Commission of India (CCI) for its composite scheme of arrangement involving Apollo Healthco Limited, Keimed Private Limited, and Apollo Healthtech Limited. The approval was granted on September 23 under Section 31(1) of the Competition Act, 2002. This scheme, initially approved by Apollo Hospitals' board on June 30, is part of the company's corporate restructuring efforts. While a significant milestone, the scheme still requires additional statutory and regulatory approvals for full implementation.

23Sept 25

Apollo Hospitals Sees Rs. 85.23 Crore Block Trade on NSE

Apollo Hospitals Enterprise Ltd. experienced a significant block trade on the National Stock Exchange (NSE), involving 111,089 shares at Rs. 7,672.00 per share, totaling Rs. 85.23 crore. This private transaction, typically executed by institutional investors, occurred outside the open market and may indicate a shift in ownership or portfolio rebalancing by a major stakeholder.

15Sept 25

Apollo Hospitals to Acquire IFC's Stake in Subsidiary, Plans Major Oncology Facility

Apollo Hospitals Enterprise plans to acquire IFC's 30.8% stake in Apollo Health and Lifestyle Limited (AHLL) for ₹1,254.07 crore, increasing its ownership to 99.42%. The company is also investing ₹573.00 crore in a new oncology facility in Gurugram, featuring advanced proton therapy technology. Apollo aims to double its oncology therapy revenue to ₹5,000.00 crore in 3-4 years. Despite these developments, the stock closed 0.19% lower, but has gained 25.9% over six months. Nomura maintains a neutral rating with a target price of ₹6,856.00.

12Sept 25

Apollo Hospitals Expands Healthcare Portfolio with ₹1,254 Crore Subsidiary Acquisition and ₹573 Crore Oncology Facility

Apollo Hospitals Enterprise Limited (AHEL) announced two major strategic moves. First, it will acquire a 30.58% stake in its subsidiary, Apollo Health and Lifestyle Limited (AHLL), for ₹12,540.68 million, increasing its ownership to 99.42%. Second, AHEL plans to establish a state-of-the-art oncology facility in Gurugram with an investment of ₹5,730 million, featuring a Single Gantry Proton Proteus One System. These initiatives aim to strengthen Apollo's position in the Indian healthcare market and support its goal of doubling its oncology business to over ₹5,000 crore in 3-4 years.

09Sept 25

Apollo Hospitals' MD Touts Healthcare Tourism as Potential Offset to US Tariff Impact

Suneeta Reddy, Managing Director of Apollo Hospitals, emphasized the potential of India's healthcare tourism sector at the 52nd National Management Convention of AIMA. She identified a $100 billion opportunity, suggesting that capturing 20% of this market could generate $20 billion by 2030, potentially offsetting losses from US tariffs. Reddy highlighted India's competitive advantages, including premium healthcare infrastructure and cost-effective clinical outcomes. She advocated for improved connectivity with countries having less developed healthcare systems and called for GST input cost reforms in the healthcare sector. Reddy also noted the positive impact of recent GST rate cuts and personal income tax reductions on consumer spending in healthcare.

04Sept 25

GST Council's Health Insurance Tax Exemption: A Boost for Healthcare Accessibility

The GST Council has exempted health insurance premiums from indirect tax, potentially making insurance more affordable and expanding coverage in India. The decision is part of broader GST reforms, including changes to tax slabs and reductions in healthcare-related taxes. Life-saving cancer and chronic care drugs will now have 0% GST, while most other medications will have 5% GST. Hospital consumables and diagnostics have been moved to the 5% GST bracket. These changes are expected to improve healthcare accessibility and affordability in the long term.

04Sept 25

Apollo Hospitals Enterprise Sees Rs. 60 Crore Block Trade on NSE

Apollo Hospitals Enterprise Ltd. experienced a significant block trade on the National Stock Exchange (NSE). Approximately 76,280 shares were traded at Rs. 7,866.00 per share, totaling around Rs. 60.00 crores. The transaction indicates substantial investor activity in the leading Indian healthcare provider's stock.

21Aug 25

Apollo Hospitals Promoter to Offload 1.25% Stake in ₹1,395 Crore Block Deal

Suneetha Reddy, a key promoter of Apollo Hospitals, plans to sell 18 lakh shares (1.25% stake) through a block deal. The transaction is valued at approximately ₹1,395.00 crore, with shares priced at ₹7,747.00 each. This sale could increase the company's free float and may impact short-term stock price movements. Apollo Hospitals, a leading Indian healthcare provider, continues to maintain a strong position in the sector.

17Aug 25

Apollo Hospitals Targets 13-14% Revenue Growth, Plans 4,400 Bed Expansion

Apollo Hospitals Enterprise aims for a 15% CAGR over the next four years, with 13-14% revenue growth from existing hospitals by FY26. The company plans to add 4,400 beds, expand through acquisitions, and focus on western and northern India. Apollo HealthCo, its digital health venture, is set for restructuring and potential listing within two years. The company is also strengthening its e-pharmacy operations with a 19-minute delivery platform in urban centers.

15Aug 25

Apollo Hospitals Founder Dr. Prathap Reddy Shares Insights on Leadership Language Show

Dr. Prathap C Reddy, founder and chairman of Apollo Hospitals, appeared on CNBC-TV18's Leadership Language show. He discussed the company's 40-year journey in transforming Indian healthcare, sharing personal insights and his guiding philosophy. The interview highlighted Apollo Hospitals' growth from its Chennai base to becoming a major private healthcare provider in India, emphasizing the challenges faced and strategies employed in revolutionizing the sector.

13Aug 25

Apollo Hospitals Reports Strong Q1 Results with 42% PAT Growth

Apollo Hospitals Enterprise Ltd announced robust Q1 financial results with 15% revenue growth to ₹5,842.00 crore, 26% EBITDA increase to ₹852.00 crore, and 42% PAT surge to ₹433.00 crore. Healthcare Services, Apollo Health and Lifestyle Limited, and Apollo HealthCo all showed significant growth. The company plans to add over 4,300 beds in the next five years with an investment exceeding ₹7,600.00 crore. Strategic initiatives include launching Apollo Zen, introducing 'Oralife' for oral cancer detection, and implementing 'Green Health' initiatives.

12Aug 25

Apollo Hospitals Reports Strong Q1 FY26 Results, Announces Expansion Plans

Apollo Hospitals Enterprise Ltd reported robust Q1 FY26 results with consolidated revenues growing 15% YoY to ₹5,842.00 crore. EBITDA increased 26% to ₹852.00 crore, and PAT surged 42% to ₹433.00 crore. The company announced plans to add over 4,300 beds in the next five years with an investment exceeding ₹7,600.00 crore. Apollo 24/7, the digital health platform, achieved a quarterly GMV of ₹682.00 crore, growing 23% YoY. The company also announced the demerger of its Omni Channel Pharmacy and Digital Health business into Apollo Healthtech Ltd.

29Jul 25

Apollo Hospitals' Shobana Kamineni Champions Women's Leadership in Business

Shobana Kamineni, executive vice-chairperson of Apollo Hospitals, shared insights on women's leadership at CNBC-TV18's Future Female Forward event in Bengaluru. She highlighted the funding disparity for women-led businesses and emphasized the importance of women's presence in key business areas. Kamineni discussed Apollo Hospitals' efforts to promote women in leadership roles, citing their loyalty and unique capabilities. She advised continuous learning and noted the potential of AI to accelerate opportunities for women. Apollo Hospitals continues to demonstrate commitment to diverse leadership and transparent communication with investors.

17Jul 25

Apollo Hospitals Sets Board Meeting for Q1 Results Review on August 12

Apollo Hospitals Enterprise Limited has announced a board meeting for August 12, 2025, to review and potentially approve unaudited financial results for Q1 FY2026 (three months ended June 30, 2025). The company has implemented a trading window closure for insiders from July 1, 2025, until 48 hours after the results announcement, expected on August 14, 2025. This meeting complies with SEBI regulations and the company's insider trading prevention policies.

16Jul 25

Apollo Hospitals in Talks to Standardize Treatment Costs Across India

Apollo Hospitals is in discussions to create a uniform pricing structure for medical treatments nationwide. This initiative aims to increase transparency, improve healthcare accessibility, and streamline operations. However, challenges include regional cost variations, maintaining quality of care, and aligning various stakeholders. The outcome could potentially reshape healthcare pricing in India.

14Jul 25

Apollo Hospitals: Rs. 34.49 Crore Block Trade Executed on NSE

A significant block trade of approximately 47,878 shares of Apollo Hospitals Enterprise Ltd. occurred on the National Stock Exchange (NSE), valued at Rs. 34.49 crore. The transaction was executed at Rs. 7,204.50 per share, potentially indicating investor interest or strategic positioning in the healthcare sector. Apollo Hospitals, a leading healthcare provider in India, operates a network of hospitals, pharmacies, and primary care clinics across the country.

08Jul 25

Apollo Hospitals: Block Trade Worth Rs. 66.71 Crores on NSE

Apollo Hospitals Enterprise Ltd. experienced a significant block trade on the National Stock Exchange (NSE). The transaction involved 87,869 shares at Rs. 7,592.50 per share, totaling Rs. 66.71 crores. This large-scale trade suggests substantial investor interest in the healthcare sector and Apollo Hospitals specifically.

02Jul 25

Apollo Hospitals Sees Major Block Trade: 72,508 Shares Sold for Rs. 54.38 Crores

Apollo Hospitals Enterprise Ltd. experienced a significant block trade on the National Stock Exchange (NSE), involving approximately 72,508 shares. The transaction was executed at Rs. 7,500.50 per share, totaling Rs. 54.38 crores. This large-scale trade suggests potential shifts in institutional or major shareholder positions within the company. Block trades of this magnitude often indicate changing investor perspectives, portfolio rebalancing, or shifts in institutional holdings.

02Jul 25

Apollo Hospitals Unveils Strategic Demerger Plan

Apollo Hospitals Enterprise Ltd. plans to demerge its core healthcare services from its digital health and pharmacy distribution business. The move aims to create two distinct entities with sharper focus and dedicated leadership. This restructuring is expected to unlock shareholder value and allow each entity to pursue unique market opportunities more effectively. The demerger could have significant implications for investors, patients, and the healthcare industry at large.

01Jul 25

Apollo Hospitals Unveils Major Restructuring Plan with New Listed Entity

Apollo Hospitals Enterprise Ltd plans to create a new listed company by consolidating its pharmacy, digital health, and pharma distribution businesses. Shareholders will receive 195.2 shares of the new company for every 100 shares held. The new entity targets ₹25,000 crore revenue by FY25 with a 7% EBITDA margin. Listing is expected within 18-21 months.

30Jun 25

Apollo Hospitals Unveils Major Restructuring Plan, Set to List Digital Health Platform

Apollo Hospitals Enterprise Limited (AHEL) has approved a restructuring plan to consolidate its digital health and pharmacy operations. The plan involves demerging and merging operations from Apollo Healthco, Keimed Private, and Apollo Healthtech to create an Omni Channel Pharmacy and Digital Health platform. Apollo Healthtech will seek listing on NSE and BSE. AHEL shareholders will receive 195.2 shares in the new entity for every 100 shares held. This move aims to streamline operations and capitalize on the growing importance of digital health solutions in the healthcare sector.

11Jun 25

Apollo Hospitals: Block Trade of 151,706 Shares Valued at Rs. 104.52 Crores

A significant block trade of approximately 151,706 shares of Apollo Hospitals Enterprise Ltd. was executed on the National Stock Exchange (NSE). The transaction was priced at Rs. 6,889.50 per share, totaling Rs. 104.52 crores. This large-scale trade indicates substantial investor interest in the healthcare sector and Apollo Hospitals specifically. While the identities of the traders remain undisclosed, such transactions typically involve institutional investors or large shareholders.

10Jun 25

Apollo Hospitals Sees Major Block Trade: 151,492 Shares Sold for Rs. 105.51 Crores

Apollo Hospitals Enterprise Ltd. experienced a significant block trade on the National Stock Exchange (NSE). The transaction involved 151,492 shares at Rs. 6,964.50 per share, totaling Rs. 105.51 crores. This large-scale trade has drawn attention from market participants, potentially indicating shifts in institutional holdings or large investors adjusting positions. The identities of the parties involved and the reasons for the trade remain undisclosed.

10Jun 25

Apollo Hospitals Sees Major Block Trade: 105,375 Shares Change Hands at Rs. 6,950 Each

Apollo Hospitals Enterprise Ltd. experienced a significant block trade on the National Stock Exchange (NSE). The transaction involved 105,375 shares, valued at Rs. 73.24 crores, with each share priced at Rs. 6,950.00. This large-scale trade indicates substantial investor interest in the company and the healthcare sector.

03Jun 25

Apollo Hospitals Shines: HSBC Raises Target Price After Robust Q4 Performance

Apollo Hospitals reported a 53.54% YoY increase in Q4 net profit to ₹414.5 crore, with revenue up 13.72%. EBITDA margin expanded by 117 basis points to 24.3%. HSBC reaffirmed 'buy' rating and raised target price by 17% to ₹8,090. The company plans a new 700-bed unit in Bengaluru and aims for cost breakeven of its digital health platform by Q3/Q4 FY2026.

02Jun 25

Apollo Hospitals: Q4 Profit Soars 53%, Beats Estimates; Analysts Maintain Positive Outlook

Apollo Hospitals Enterprise reported strong Q4 results with a 53.50% year-over-year increase in consolidated net profit to ₹390.00 crore. Revenue rose by 13.00% to ₹5,592.00 crore. The company announced plans to expand in Bengaluru with 700 new beds. The board recommended a final dividend of ₹10.00 per share. Analysts maintain 'Buy' ratings with price targets ranging from ₹6,856 to ₹8,260.

01Jun 25

Apollo Hospitals Projects Healthco Cash EBITDA Breakeven by Q2/Q3 FY26

Apollo Hospitals anticipates its digital health initiative, Healthco, to achieve cash EBITDA breakeven by Q2/Q3 FY26, excluding ESOP costs. The company projects 25-30% YoY GMV growth for FY26 and expects the sales to GMV ratio to improve from 37% in FY25 to 40-45% in FY26. These projections indicate a strong focus on scaling Healthco's operations and improving its financial performance.

31May 25

Apollo Hospitals Unveils Ambitious Growth Strategy, Targets Rs 250 Billion Revenue by FY27

Apollo Hospitals has announced a comprehensive growth strategy focusing on international expansion beyond Bangladesh, aggressive pharmacy network growth with 600 new stores annually, and ambitious financial targets. The company aims to achieve Rs 250 billion in revenue by FY27, with a 24% CAGR from FY25 to FY27 and an EBITDA margin of 7-8%. This strategy emphasizes geographic diversification, expanding retail pharmacy presence, and maintaining profitability during rapid expansion.

31May 25

Apollo Hospitals Unveils Ambitious Expansion Plan with 1,937 New Beds

Apollo Hospitals has unveiled plans to add 1,937 beds, including 1,577 census beds, across seven projects. The expansion, estimated to cost Rs 3,165.00 crore, aims to significantly boost the company's healthcare capacity. A substantial portion of the investment, Rs 1,833.00 crore, is earmarked for fiscal year 2026.

30May 25

Apollo Hospitals: Rs 6,000 Crore Investment for 4,300 New Beds and Expansion in Bengaluru

Apollo Hospitals Enterprise Ltd plans to invest Rs 6,000 crore over 3-4 years to add 4,300 beds across India, with 2,000 beds expected within 12-15 months. In Bengaluru, the company will invest Rs 1,229 crore, including Rs 944 crore for land to develop a 500-bed hospital and Rs 285 crore to acquire an existing hospital. The company reported strong financial results with Q4 consolidated revenue up 13% to Rs 5,592 crore and net profit up 54% to Rs 390 crore. A final dividend of Rs 10 per share was announced.

30May 25

Apollo Hospitals: Q4 Profit Surges 59%, Beats Estimates

Apollo Hospitals announced strong Q4 results with consolidated net profit rising 59.30% to ₹411.50 crore. Revenue increased by 13.10% to ₹5,592.20 crore, while EBITDA grew 20.20% to ₹769.70 crore. The EBITDA margin improved to 13.76% from 12.96%. The company declared a dividend of ₹10.00 per share.

16May 25

Apollo Hospitals Enterprise Announces Internal Restructuring Plan

Apollo Hospitals Enterprise is implementing an internal restructuring plan, amalgamating Apollo Amrish Oncology Services Pvt Ltd (AAOSPL) with Apollo Hospitals International Ltd (AHIL), a wholly owned subsidiary. This move aims to streamline operations, potentially enhance oncology services, and optimize resource allocation within the group.

09May 25

Apollo Hospitals Sees Rs. 20.56 Crore Block Trade on NSE

A significant block trade of approximately 30,755 shares of Apollo Hospitals Enterprise Ltd. occurred on the National Stock Exchange (NSE). The shares were traded at Rs. 6,683.50 per share, totaling around Rs. 20.56 crore. This transaction highlights ongoing interest in the healthcare sector and Apollo Hospitals, one of India's largest integrated healthcare providers.

11Apr 25

Apollo Hospitals Sets Sights on Northern India Expansion Through Acquisitions

Apollo Hospitals Enterprise Ltd. plans to add 3,500 beds over the next 3-4 years, focusing on major cities like Kolkata, Hyderabad, and Mumbai. The company aims to strengthen its presence in northern India through strategic acquisitions. Apollo is also investing ₹240 crore in a new cancer center and focusing on high-growth specialties such as oncology, cardiac care, neurology, and preventive healthcare. This expansion strategy targets key urban centers and specialized care to capture a larger market share and enhance capabilities in high-demand medical areas.

24Mar 25

Apollo Healthco Expands Healthcare Footprint with 11.2% Stake in Keimed

Apollo Healthco, a subsidiary of Apollo Hospitals Enterprise Limited, has acquired an 11.2% stake in Keimed Private Limited for ₹6.25 billion ($75 million). This strategic move aims to strengthen Apollo Hospitals' market position in the Indian healthcare sector, potentially expanding its market reach, creating synergies, and diversifying its portfolio.

21Mar 25

Apollo Healthco Acquires 11.2% Stake in Keimed for ₹625.43 Crore

Apollo Hospitals Enterprise Limited's subsidiary, Apollo Healthco Limited, has completed the acquisition of an 11.2% stake in Keimed Private Limited for ₹625.43 crore. The transaction involved purchasing shares from a promoter and making a primary investment into Keimed. The deal was completed on March 20, 2025, following board approval in April 2024.

13Mar 25

Apollo Hospitals to Boost AI Investment, Aiming to Streamline Operations and Expand Capacity

Apollo Hospitals plans to increase investment in AI tools to automate routine tasks and reduce workload for medical staff, potentially saving 2-3 hours daily. The AI initiative focuses on diagnosis suggestions, medical transcription, and antibiotic prescription assistance. The company also aims to expand bed capacity by one-third over four years, partly funded by AI-driven cost savings.

10Mar 25

Apollo Hospitals Sees Significant Block Trade on NSE

A significant block trade of Apollo Hospitals Enterprise Ltd. shares occurred on the National Stock Exchange (NSE). The transaction involved 30,058 shares at Rs. 6,165.90 per share, totaling Rs. 18.53 crores. This large-scale trade has drawn market attention due to its potential implications for the company's stock and possible shifts in institutional holdings or investor perspectives.

05Mar 25

Apollo Hospitals Expands Cancer Care with Rs 250 Crore Investment in Proteus One System

Apollo Hospitals Enterprise Ltd plans to invest Rs 250 crore in a new Comprehensive Oncology Centre featuring India's first Proteus One Proton System. The project, to be completed by FY 2028, will add capacity for 350 patients annually. Apollo has partnered with Ion Beam Applications (IBA) for this expansion. Concurrently, a block trade of 30,325 shares at Rs 6,170.60 per share was executed on the NSE.

05Mar 25

Apollo Hospitals to Invest ₹250 Crore in Cutting-Edge Oncology Centre, Partnering with IBA for Proteus One System

Apollo Hospitals Enterprise Limited (AHEL) is investing ₹250 crore to establish a comprehensive oncology centre, featuring India's first Proteus One Proton System. The facility, set to open by FY 2028, will increase proton therapy treatment capacity by 350 patients annually, bringing the total capacity to 1,200 patients per year. This expansion addresses India's growing cancer care needs, as the country ranks third globally in new cancer incidences. The investment will be financed through internal accruals over three years.

04Mar 25

Apollo Hospitals to Invest ₹250 Crore in India's First Proteus One Proton Therapy System in Hyderabad

Apollo Hospitals Enterprise Limited plans to invest ₹250 crore over three years to establish a Comprehensive Oncology Centre in Hyderabad, featuring India's first Proteus One Proton System. The centre, set to be operational by FY2028, will have the capacity to treat an additional 350 patients annually. This investment aims to address India's growing cancer care needs, with the country expected to see 1.5 million new cancer cases this year.

25Feb 25

Apollo Hospitals Sees Rs. 22.01 Crore Block Trade on NSE

A significant block trade of 35,216 shares of Apollo Hospitals Enterprise Ltd. occurred on the National Stock Exchange at Rs. 6,250.50 per share, totaling Rs. 22.01 crores. The transaction, potentially indicating institutional activity or large stakeholder movements, has drawn market attention. Apollo Hospitals, a leading Indian healthcare provider, continues to be a key player in the sector.

21Feb 25

Apollo Hospitals Unveils ₹6,000 Crore Expansion Plan to Add 3,000 Beds Across India

Apollo Hospitals announces a ₹6,000 crore investment over three years to add 3,000 beds across major Indian cities including Mumbai, Gurgaon, Hyderabad, Chennai, and Bengaluru. The expansion plan includes growing their hospital network, pharmacy chain, clinic network, and digital health services. The company's pharmacy division has recently achieved mild profitability.